Literature DB >> 21130230

[French translation and validation of the Scale to assess Unawareness of Mental Disorder (SUMD) in patients with schizophrenics].

C Paillot1, P Ingrand, B Millet, X-F Amador, J-L Senon, J-P Olié, N Jaafari.   

Abstract

BACKGROUND: The Scale to assess Unawareness of Mental Disorder (SUMD) is a semi-structured interview based on a dimensional and quantitative approach of insight. Different forms of insight are assessed: global insight into mental illness, insight into symptoms and insight into symptom aetiology (i.e. attribution). The SUMD divides the recognition of mental disorders into two concepts: awareness of, and attribution for mental disorders. Awareness relates to the subject's ability to recognize that the phenomenon in question is present, whereas attribution refers to explanations as to cause or source of these signs or symptoms. Thus, the scale distinguishes between the recognition of a symptom and its explanation. For example, the scale allows the investigator to distinguish between a patient's ability to recognize visual hallucinations as such (false perceptions), from his/her ability to explain their cause (e.g. due to mental illness or not).
OBJECTIVE: The aim of this study was to translate the SUMD (version 3.1 revised) and test its convergent validity among 43 French adult inpatients diagnosed with schizophrenia according to DSM-IV-TR criteria.
METHODS: Awareness of mental disorder was assessed using the SUMD and the Hamilton Rating Scale for Depression (HAMD) insight item (item 17) respectively, as done in the original English validation study. The SUMD was translated into French then back-translated into English. The back-translation was performed by both English and French native speakers who had no prior knowledge of the scale (the back translation was reviewed by one of the SUMD's authors, Dr Amador, for accuracy). The SUMD manual (v.2/14/99) was also translated into French. Concerning the SUMD directions followed in this study, the first three SUMD items, which are called general items: G1 "Awareness of mental disorder", G2 "Awareness of the achieved effects of medication" and G3 "Awareness of the social consequences of mental disorder" were systematically rated. However, symptom items (four through 20) are not always relevant for every patient. Indeed, for each symptom-item on the scale, it must first be ascertained that the patient has exhibited the particular symptom during the period under investigation. Therefore, for every patient, the symptom checklist was completed prior to filling out the scale, in order to determine which symptom-items were relevant. In addition, symptom attribution items are rated only if the subject received a score between 1 and 3 on the awareness item. Two periods of time of insight were assessed: "current" insight involved rating the highest level of awareness obtained at the time of the interview for the psychopathology present at anytime during the past 7 days. "Past" insight was defined as the present level of awareness during the period of time preceding the current period of investigation.
RESULTS: The French translation of the SUMD achieved good convergent validity with the insight item of the Hamilton rating scale for depression. DISCUSSION: The SUMD has proven to be a reliable and valid instrument to assess insight into schizophrenia. The more psychometrically sound rating tools we have at our disposal, many of which have been published in non French journals, the more we will be able to sharpen our assessment of insight into schizophrenia. We are facing an epistemic paradox in which quantification helps description, i.e. we need to have access to different rating tools to measure insight in order to improve our knowledge of the causes, course and treatment of poor insight into mental disorders.
Copyright © 2010 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21130230     DOI: 10.1016/j.encep.2009.12.008

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  4 in total

Review 1.  Systematic review reveals heterogeneity in the use of the Scale to Assess Unawareness of Mental Disorder (SUMD).

Authors:  Rémy Dumas; Karine Baumstarck; Pierre Michel; Christophe Lançon; Pascal Auquier; Laurent Boyer
Journal:  Curr Psychiatry Rep       Date:  2013-06       Impact factor: 5.285

2.  High-Frequency Neuronavigated rTMS in Auditory Verbal Hallucinations: A Pilot Double-Blind Controlled Study in Patients With Schizophrenia.

Authors:  Sonia Dollfus; Nemat Jaafari; Olivier Guillin; Benoit Trojak; Marion Plaze; Ghassen Saba; Cécilia Nauczyciel; Aurélie Montagne Larmurier; Nathalie Chastan; Vincent Meille; Marie-Odile Krebs; Samar S Ayache; Jean Pascal Lefaucheur; Annick Razafimandimby; Elise Leroux; Rémy Morello; Jean Marie Batail; Perrine Brazo; Nicolas Lafay; Issa Wassouf; Ghina Harika-Germaneau; Remy Guillevin; Carole Guillevin; Emmanuel Gerardin; Maud Rotharmel; Benoit Crépon; Raphael Gaillard; Christophe Delmas; Gael Fouldrin; Guillaume Laurent; Clément Nathou; Olivier Etard
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

3.  Examining transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia (STIM'Zo): a study protocol for a multicentre, double-blind, randomized sham-controlled clinical trial.

Authors:  Jerome Brunelin; Marine Mondino; Julie Haesebaert; Jerome Attal; Michel Benoit; Marie Chupin; Sonia Dollfus; Wissam El-Hage; Filipe Galvao; Renaud Jardri; Pierre Michel Llorca; Laurent Magaud; Marion Plaze; Anne Marie Schott-Pethelaz; Marie-Françoise Suaud-Chagny; David Szekely; Eric Fakra; Emmanuel Poulet
Journal:  Trials       Date:  2021-12-28       Impact factor: 2.279

4.  Psychiatric advance directives for people living with schizophrenia, bipolar I disorders, or schizoaffective disorders: Study protocol for a randomized controlled trial - DAiP study.

Authors:  Aurélie Tinland; Léa Leclerc; Sandrine Loubière; Frederic Mougeot; Tim Greacen; Magali Pontier; Nicolas Franck; Christophe Lançon; Mohamed Boucekine; Pascal Auquier
Journal:  BMC Psychiatry       Date:  2019-12-27       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.